Ownership Action Don’t Lie: Stryker Corp (NYSE:SYK) Institutional Investors Sentiment

November 24, 2016 - By Ruchi Gupta   ·   0 Comments

Ownership Action Don't Lie: Stryker Corp (NYSE:SYK) Institutional Investors Sentiment

Sentiment for Stryker Corp (NYSE:SYK)

Stryker Corp (NYSE:SYK) institutional sentiment decreased to 0.79 in 2016 Q2. Its down -0.14, from 0.93 in 2016Q1. The ratio turned negative, as 341 investment managers opened new or increased stock positions, while 366 sold and decreased their stakes in Stryker Corp. The investment managers in our partner’s database now have: 279.01 million shares, down from 285.46 million shares in 2016Q1. Also, the number of investment managers holding Stryker Corp in their top 10 stock positions increased from 44 to 51 for an increase of 7. Sold All: 41 Reduced: 325 Increased: 280 New Position: 61.

Stryker Corporation is a medical technology company. The company has a market cap of $41.56 billion. The Firm operates through three divisions: Orthopaedics, MedSurg, and Neurotechnology and Spine. It has a 25.48 P/E ratio. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries.

The stock increased 0.94% or $1.04 on November 23, hitting $111.75. About 1.42 million shares traded hands. Stryker Corporation (NYSE:SYK) has risen 2.15% since April 22, 2016 and is uptrending. It has underperformed by 3.26% the S&P500.

Analysts await Stryker Corporation (NYSE:SYK) to report earnings on January, 24. They expect $1.76 EPS, up 12.82% or $0.20 from last year’s $1.56 per share. SYK’s profit will be $654.55M for 15.87 P/E if the $1.76 EPS becomes a reality. After $1.39 actual EPS reported by Stryker Corporation for the previous quarter, Wall Street now forecasts 26.62% EPS growth.

According to Zacks Investment Research, “Stryker Corporation develops, manufactures, and markets specialty surgical and medical products, including orthopaedic implants, bone cement, trauma systems used in bone repair, powered surgical instruments, endoscopic systems, craniomaxillofacial fixation devices, specialty surgical equipment used in neurosurgery and patient care and handling equipment for the global market and provide outpatient physical and occupational rehabilitation services.”

Greenleaf Trust holds 83.09% of its portfolio in Stryker Corporation for 27.07 million shares. Cabot owns 88,261 shares or 8.81% of their US portfolio. Moreover, Tukman Grossman Capital Management Inc has 8.68% invested in the company for 1.23 million shares. The -based Bonness Enterprises Inc has invested 7.92% in the stock. Fundsmith Llp, a United Kingdom-based fund reported 3.93 million shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 2 insider buys, and 64 insider sales for $86.25 million net activity.

Stryker Corporation (NYSE:SYK) Ratings Coverage

Ratings analysis reveals 58% of Stryker Corporation’s analysts are positive. Out of 19 Wall Street analysts rating Stryker Corporation, 11 give it “Buy”, 2 “Sell” rating, while 6 recommend “Hold”. The lowest target is $88 while the high is $130. The stock’s average target of $109.83 is -1.72% below today’s ($111.75) share price. SYK was included in 25 notes of analysts from July 27, 2015. The rating was initiated by Suntrust Robinson with “Buy” on Friday, October 14. As per Friday, October 14, the company rating was initiated by SunTrust. The rating was initiated by Sterne Agee CRT with “Neutral” on Wednesday, November 4. The rating was maintained by Stifel Nicolaus on Wednesday, August 12 with “Buy”. The firm has “Buy” rating by Argus Research given on Wednesday, August 5. On Monday, December 14 the stock rating was downgraded by BMO Capital Markets to “Underperform”. Needham downgraded Stryker Corporation (NYSE:SYK) on Monday, September 28 to “Hold” rating. Brean Capital upgraded Stryker Corporation (NYSE:SYK) on Wednesday, January 27 to “Buy” rating. The firm earned “Outperform” rating on Friday, July 24 by RBC Capital Markets. On Wednesday, April 27 the stock rating was maintained by Argus Research with “Buy”.

SYK Company Profile

Stryker Corporation (Stryker), incorporated on February 20, 1946, is a medical technology company. The Firm operates through three divisions: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Firm offers its products to doctors, hospitals and other healthcare facilities. The Company’s products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment, and neurosurgical, neurovascular and spinal devices, as well as other medical device products used in a range of medical specialties. The Company’s products are sold in approximately 100 countries through the Company-owned sales subsidiaries and branches, as well as third-party dealers and distributors. The Firm offers a 1588 advanced imaging modalities (AIM) platform, which is designed for optimum visualization across surgical specialties.

Another recent and important Stryker Corporation (NYSE:SYK) news was published by Businesswire.com which published an article titled: “Study To Be Presented at NASS 2016 Evaluating Bone In-Growth for Stryker’s 3D …” on October 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta

Tags: , ,

Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News